Cancer Conversations Podcast – Episode #11: Advances in Pediatric Brain Tumor Treatment

Mark Kieran, MD, PhD

Mark Kieran, MD, PhD, focuses on pediatric brain tumor patients in the clinic and in the lab.

Perhaps more than any other childhood cancer, pediatric brain tumor treatment is incredibly complex and takes a team effort to care for a patient. Doctors and researchers are working to not only improve medicines and treatment methods, they are also striving to improve quality of life and long-term side effects for young patients.

“The goal isn’t to have just one person treat a child, it’s about having several people all putting together their expertise to care for the patient,” says Mark Kieran, MD, PhD, clinical director of the Pediatric Brain Tumor Center at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

In this Cancer Conversations podcast episode, Kieran joins Peter Manley, MD, a pediatric neuro-oncologist and director of the Stop & Shop Family Pediatric Neur-Oncology Outcomes Clinic, for a discussion on the latest in pediatric brain tumor treatment. Kieran and Manley discuss precision medicine, immunotherapy, and radiation therapy, as well as new information about the long-term survival of patients and ways to reduce treatment side effects.

Listen to the podcast episode below or click “download” to listen later. Subscribe options are also available via iTunes, Google Play, the Stitcher app, TuneIn app, and RSS.

The Cancer Conversations series features Q&A-style conversations with Dana-Farber physicians, clinicians, and researchers. Topics include breast cancer research, precision cancer medicine, integrative therapies, cancer genetics, and more. Visit the Cancer Conversations page for more episodes and the Dana-Farber podcast page for more cancer podcast series.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Dana-Farber clinicians have been involved in the development of several new agents approved recently for B-cell acu… https://t.co/Oo3SiY79EN
Dana-Farber @danafarber
Dana-Farber #researchers have shown that clonal hematopoiesis of indeterminate potential (CHIP) - the presence of s… https://t.co/ZlmXSeyKfZ
Dana-Farber @danafarber
CRISPR, a powerful new tool for editing the #DNA instruction manual in animals and humans, is proving a boon to… https://t.co/pCzS3riHPS

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.